Recursion (NASDAQ: RXRX) director granted 4,902 Class A shares as compensation

Rhea-AI Filing Summary

Dar Zavain reported acquisition or exercise transactions in this Form 4 filing.

RECURSION PHARMACEUTICALS, INC. director Zavain Dar received a grant of 4,902 shares of Class A Common Stock. The shares were issued at no cash cost to him under the company’s Outside Director Compensation Policy and are reported as directly owned. Following this award, he holds 147,231 Class A shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dar Zavain

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	4,902	$0.00	--

Holdings After Transaction: Class A Common Stock — 147,231 shares (Direct)

Footnotes (1)

1. [object Object]

Key Figures

Shares granted: 4,902 shares Grant price: $0.00 per share Shares owned after grant: 147,231 shares

3 metrics

Shares granted 4,902 shares Class A Common Stock award on April 1, 2026

Grant price $0.00 per share Reported transaction price for director equity grant

Shares owned after grant 147,231 shares Director’s direct Class A holdings following the transaction

Key Terms

Outside Director Compensation Policy, Class A Common Stock, Form 4

3 terms

Outside Director Compensation Policy financial

"The shares were issued pursuant to the Issuer's Outside Director Compensation Policy."

Class A Common Stock financial

"security_title: Class A Common Stock"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dar Zavain

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UTAH 84101

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	04/01/2026		A(1)		4,902	A	$0	147,231	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were issued pursuant to the Issuer's Outside Director Compensation Policy.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did RXRX director Zavain Dar report?

Zavain Dar reported receiving 4,902 shares of RECURSION PHARMACEUTICALS Class A Common Stock. The shares were granted as part of his director compensation and not bought on the open market, reflecting routine equity-based pay.

Was the RXRX insider transaction a stock purchase or a grant?

The transaction was a stock grant, not a purchase. Zavain Dar received 4,902 Class A shares at a reported price of $0.00 per share under the company’s Outside Director Compensation Policy as part of non-cash compensation.

How many RXRX shares does Zavain Dar own after this Form 4?

After the reported grant, Zavain Dar directly owns 147,231 shares of RECURSION PHARMACEUTICALS Class A Common Stock. This figure includes the new 4,902-share award disclosed in the Form 4 insider filing for April 1, 2026.

What is the significance of the Outside Director Compensation Policy for RXRX?

The Outside Director Compensation Policy governs how non-employee directors like Zavain Dar are paid in equity. Under this policy he received 4,902 Class A shares, aligning director compensation with shareholder interests through stock ownership rather than cash.

Did RXRX director Zavain Dar sell any shares in this Form 4?

No sales were reported in this Form 4. The filing shows a single acquisition transaction coded as a grant of 4,902 Class A shares, increasing his direct holdings to 147,231 shares with no dispositions indicated.